Shownotes
Monday Immune Engager — our weekly pick from the latest immune-engager digest.
Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism
Nature, 2026
DOI: 10.1038/s41586-026-11176-1
Question: Can IL-10 receptor agonism be made to suppress myeloid cells without also activating T cells, which drives IL-10's clinical toxicity?
Answer: A tetravalent nanobody agonist (lead E07/A05) suppresses macrophage TNF/IL-6 with low-picomolar potency while leaving T cells silent, via a binding geometry that makes signalling strictly TYK2-dependent and sensitive to receptor density…
Website: raymondruff.github.io

